【聚焦】复星医药猛攻240亿市场,新品欲抢国内首仿

米内网
Aug 13

精彩内容8月13日,复星医药(徐州)提交了瑞维那新吸入溶液4类仿制上市申请获得CDE承办。该产品是一款呼吸系统吸入剂,迈兰的原研产品于今年6月获批进口。目前复星医药报产在审的呼吸系统用药中有6款为吸入剂,集团正全力抢攻这个240亿热销市场。图1:复星医药(徐州)最新申报的产品来源:CDE官网图2:迈兰的瑞维那新吸入溶液项目情况来源:米内网项目进度数据库瑞维那新吸入溶液是迈兰开发的一款长效毒蕈碱...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10